The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms.
The diagnosis and assignment of grade in neoplasms of the central nervous system (CNS), for the most part, are morphologically based and predicated on the interpretation of descriptions of what the phenotypic findings are for a particular tumor type. Not surprisingly, the application of various grading systems in CNS neoplasia has been limited somewhat by interobserver variability. Since assignment of grade and tumor type is the basis upon which therapeutic intervention is grounded, investigators have been searching for ancillary means by which morphologically based systems can be improved. Utilization of cell proliferation markers in the evaluation of tumors can be potentially useful in this endeavor. This review focuses on issues surrounding the utilization of MIB-1 or Ki-67 antibody in the evaluation of CNS neoplasms.
Prayson
Richard A
RA
Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. praysor@ccf.org
D000974:Antibodies, Antinuclear / Q000032:analysis*; D000911:Antibodies, Monoclonal / Q000032:analysis*; D001254:Astrocytoma / Q000276:immunology / Q000473:pathology; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000473:pathology*; D005910:Glioma / Q000276:immunology / Q000473:pathology; D005911:Gliosis / Q000276:immunology / Q000473:pathology; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis*; D008579:Meningioma / Q000473:pathology; D013194:Staining and Labeling
D000974:Antibodies, Antinuclear; D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; C440408:MIB-1 antibody